FDA approval of Mirvaso®: the first FDA-approved topical treatment specifically developed and indicated for the facial erythema of rosacea

Galderma Laboratories, L.P. has announced that the U.S. Food and Drug Administration (FDA) has approved Mirvaso® (brimonidine) topical gel, 0.33%* for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Dermatology Source Type: news